Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date

It has been nearly a year and a half since my previous Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ) article . Then, I highlighted the company's flagship candidate, cosibelimab, or "Cosi," and its potential to receive dual-approval in locally advanced and metastaticHe is the leader of the investing group Compounding Healthcare . Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn moreBiologics is a full-time h ...